"Our study documented higher gender-affirming hormone continuation rates among transfeminine individuals and by patients who started hormones before reaching the age of legal majority in a population with universal insurance and access to low or no-cost medical and pharmaceutical care. Family socioeconomic status, family member type, and the official status of gender-affirming care as a TRICARE-covered benefit at the time the patient began taking gender-affirming hormones had no influence on continuation of gender-affirming hormones. We noted a higher hormone continuation rate among TGD individuals who were younger than 18 years old at the time of first use of gender-affirming hormones compared with those who were aged 18 years and older when starting hormones. This has not been documented in previous studies"